OakChart

Palvella Therapeutics Inc

PVLAHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

163.94-4.77 (-2.83%)
2026-11-12 00:30 CET
Market cap
2,466.29 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-74.99 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-5.51
P/E
-
Compare

Price

PVLA against its 20, 50 and 200-day averages
2050200missearnings
100.00125.00150.00175.00586K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PVLAclose 163.9420-day 143.9050-day 143.61200-day 129.72163.9452w high

8.9% under the 52-week high of 179.95 on 9 Nov 2026. 52-week low 72.23 on 30 Jan 2026. Last 15 sessions, 48.3% high to low

Volume 1.03× normal · the line is the 50-bar volume average

Profile

PVLA
52-week range, 85% of the way up
72.22179.95

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

IndexRUT
Employees29
IPOJan 02, 2015
Beta-0.27
ATR, 14d9.59
Rel volume1.03
Short float27.97%
Insider own36.41%
Inst own94.16%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.40B
Enterprise Value2.18B
Income-74.99M
Sales0.00M
Book/sh12.49
Cash/sh16.19
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees29
IPOJan 02, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B13.12
P/C10.13
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio21.18
Current Ratio16.01
Debt/Eq0.11
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.51
EPS next Y-8.12
EPS next Q-1.96
EPS this Y-70.06%
EPS next Y-28.74%
EPS next 5Y-18.38%
EPS past 3/5Y53.08% 41.62%
Sales past 3/5Y- -
EPS Y/Y TTM56.34%
Sales Y/Y TTM-
EPS Q/Q-65.38%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.4.68% -

Ownership

Insider Own36.41%
Insider Trans-1.50%
Inst Own94.16%
Inst Trans11.61%
ROA-48.96%
ROE-63.39%
ROIC-31.34%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2013.93%
SMA5014.15%
SMA20026.38%
Trades-

Technical

Shs Outstand15.84M
Shs Float9.30M
Short Float27.97%
Short Ratio11.05
Short Interest2.60M
52W High179.95 -8.90%
52W Low72.22 126.99%
Volatility9.09% 6.57%
ATR (14)9.59
RSI (14)61.43
Beta-0.27
Rel Volume1.03
Avg Volume235.44K
Volume241,532

Performance

Perf Week1.02%
Perf Month27.57%
Perf Quarter4.72%
Perf Half Y35.97%
Perf YTD56.63%
Perf Year110.58%
Perf 3Y747.85%
Perf 5Y-47.86%
Perf 10Y35.57%
Recom1.00
Target Price232.94
Prev Close168.71
Price163.94
Change %-2.83%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Sep 21, 2026ResumedCChardan Capital MarketsBuy$240+46.4%
May 12, 2026InitiatedSStephensOverweight$220+34.2%
Jan 07, 2026InitiatedMMizuhoOutperform$205+25.0%
Dec 05, 2025InitiatedBBTIG ResearchBuy$167+1.9%
Dec 04, 2025InitiatedCCraig HallumBuy$175+6.7%
Nov 19, 2025UpgradeRRaymond JamesOutperform → Strong Buy$143-12.8%
Sep 09, 2025InitiatedOOppenheimerOutperform$85-48.2%
Aug 06, 2025InitiatedRRaymond JamesOutperform$54-67.1%
Jul 21, 2025InitiatedTTruistBuy$56-65.8%

Peers

Mkt cap
TickerCompanyMkt cap
KRYSKrystal Biotech Inc9.15B
ABEOAbeona Therapeutics Inc131.44M
ARQTArcutis Biotherapeutics Inc3.59B
MANEVeradermics Inc6.54B
NVSNovartis AG ADR293.47B
ACRSAclaris Therapeutics Inc688.38M
INCYIncyte Corp24.92B
MIRMMirum Pharmaceuticals Inc6.18B
ORKAOruka Therapeutics Inc7.27B
VRCAVerrica Pharmaceuticals Inc67.17M

Insider trading

latest 14 of 52
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
JEFFREY MARTINIOfficerNov 10 '26Proposed Sale174.0850,0008,704,000Nov 10 04:28 PM
Goin KathleenChief Operating OfficerOct 21 '26Option Exercise8.114,31334,9624,313Oct 23 04:05 PM
Goin KathleenChief Operating OfficerOct 21 '26Sale124.584,313537,3070Oct 23 04:05 PM
Goin KathleenOfficerOct 21 '26Proposed Sale123.924,313534,467Oct 21 04:21 PM
JENKINS GEORGE MDirectorOct 12 '26Sale133.6913,1521,758,330146,964Oct 14 07:14 PM
JENKINS GEORGE MDirectorOct 13 '26Sale130.367,174935,232139,790Oct 14 07:14 PM
JENKINS GEORGE MDirectorOct 14 '26Sale123.497,174885,914132,616Oct 14 07:14 PM
JENKINS GEORGE MDirectorOct 13 '26Proposed Sale134.3827,5003,695,450Oct 13 04:59 PM
Goin KathleenChief Operating OfficerSep 16 '26Option Exercise8.114,30234,8834,302Sep 18 04:05 PM
Goin KathleenChief Operating OfficerSep 16 '26Sale152.244,302654,9230Sep 18 04:05 PM
Goin KathleenOfficerSep 16 '26Proposed Sale151.224,302650,548Sep 16 04:31 PM
JENKINS GEORGE MDirectorSep 14 '26Sale151.9613,3522,028,905161,893Sep 15 09:15 PM
JENKINS GEORGE MDirectorSep 11 '26Sale151.2812,3711,871,435175,245Sep 15 09:15 PM
JENKINS GEORGE MDirectorSep 15 '26Sale150.141,777266,806160,116Sep 15 09:15 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VHTVanguard Health Care ETFAUM: 21.51B
PTHInvesco Dorsey Wright Healthcare Momentum ETFAUM: 291.00M
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M

News

latest 14 of 200
  • Palvella's Narrow Miss Is A Sideshow: Priority Review Sets A February 2027 Verdict As Launch Spending Accelerates (Earnings Whispers)
  • Palvella Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference (GlobeNewswire)
  • Palvella's Q3 Report Hinges On NDA Completion Timing And Disciplined Launch Spending (Earnings Whispers)
  • Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 (GlobeNewswire)
  • Palvella Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set (GlobeNewswire) +10.95%
  • Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference (GlobeNewswire)
  • Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference (GlobeNewswire)
  • Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 (GlobeNewswire)
  • U.S. Food and Drug Administration Awards Additional Funding for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire)
  • Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth (Business Wire)
  • Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer (GlobeNewswire)
  • Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.700-1.784-1.7000.000.0016
2026Q22026-08-04-1.520-1.173-1.5230.000.0016
2026Q12026-05-07-1.200-0.935-1.2050.000.0014
2025Q42026-03-31-1.080-0.911-1.0820.000.0016
2025Q32025-11-11-1.030-0.838-1.0250.000.0012
2025Q22025-08-14-0.860-0.741-0.8570.000.0012
2025Q12025-05-15-0.740-1.211-0.7430.000.008
2024Q42025-03-31-1.037-0.638-1.4500.000.008
2024Q32024-10-30-1.357--2.1870.00--
2023Q22023-08-034.000-12.5363.62220.064.021
2023Q12023-05-10-14.400-14.680-14.1531.942.722
2022Q42023-03-29-8.800-18.360-8.7055.846.512
2022Q32022-11-02-10.400-12.800-10.4705.374.512
2022Q22022-08-04-11.200-8.800-11.1583.7010.472
2022Q12022-05-11-5.600-9.200-5.53610.9911.302
2021Q42022-03-01-12.000-10.800-10.5588.448.202

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-40.000-38.200-40.32229.1030.08
2019FY-44.800-60.800-44.71946.2833.82
2020FY-54.400-52.800-54.66929.3231.25
2021FY-56.800-56.400-56.68831.4231.41
2022FY-36.000-50.744-35.89225.9026.57
2024FY-7.830-2.842-7.8320.000.03
2025FY-3.710-3.518-3.7100.000.00
2026FY--6.309--0.00
2027FY--8.123--20.81
2028FY--6.156--100.34
2029FY-0.805--278.61
2030FY-12.741--606.53

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0513000.000.000.00
2026Q4S2026-10-1413000.000.000.00
2026Q4S2026-09-1812000.000.000.00
2026Q4S2026-08-2711000.000.000.00
2026Q4S2026-08-0412000.000.000.00
2026Q4S2026-07-2112000.000.000.00
2026Q4S2026-07-0512010.000.000.00
2026Q4S2026-05-0713010.000.000.00
2026Q4S2026-03-3111000.020.000.20
2026Q4S2026-01-069000.020.000.20
2026Q4S2025-12-038000.030.000.20
2026Q4S2025-11-116000.030.000.20
2026Q4S2025-11-106000.030.000.20
2026Q4S2025-11-096000.030.000.20

Estimate history

EPS, annual-32.136-40.322-44.719-54.669-56.688-35.892798.894-7.832-3.708-5.5057
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.764-2.187-0.743-0.857-1.025-1.082-1.205-1.523-1.696
PeriodQ2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual25.27529.10146.27929.32331.41825.9020000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.5630.6770.690.70.9030.9310.02211.01212.38115.845
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.321.3211.02111.0611.08812.38114.31414.39615.845
PeriodQ2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.0025.9031.4229.3246.2829.10
Cost of Goods Sold Incl. D&A0.000.000.000.002.782.37---
Gross Profit0.000.000.000.0023.1229.05---
Selling, General and Administrative Excl. Other70.2938.6014.1011.8766.6080.8861.1272.4059.36
Research and Development39.7522.848.158.7950.2164.2044.2254.3640.92
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-70.29-38.60-14.10-11.87-43.47-51.83-33.92-27.16-30.83
Interest Expense-5.824.320.000.000.000.000.000.00
Unusual Expense-0.611.51-23.58-----
Net Income Before Taxes-74.99-41.72-17.4318.69-33.28-45.74-37.07-25.47-27.07
Income Taxes0.000.000.000.000.000.000.160.00-0.31
Consolidated Net Income-74.99-41.72-17.4318.69-33.28-45.74-37.23-25.47-26.75
Net Income From Continuing Operations-74.99-41.72-17.4318.69-33.28-45.74-37.23-25.47-26.75
Net Income-74.99-41.72-17.4317.91-33.28-45.74-37.23-28.30-26.75
EPS (Recurring)-5.16-3.67-7.3662.74-35.89-56.69-54.67-44.72-40.32
EPS (Basic, Before Extraordinaries)-5.51-3.71-7.83809.64-35.89-56.69-54.67-44.72-40.32
EPS (Diluted)-5.51-3.71-7.83798.89-35.89-56.69-54.67-44.72-40.32
EBITDA--38.60-14.10-11.87-40.69-49.46-31.79-26.12-30.26
Non-Operating Income (Expense)-2.053.322.496.9810.206.09-3.151.693.77
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-6.400.830.604.405.213.725.373.90
Price To Sales Ratio---0.382.987.774.643.964.85
Gross Margin----89.2792.46---
Operating Margin-----167.84-164.97-115.68-58.68-105.94
Net Margin-----128.47-145.58-126.97-61.15-91.93
Shares Outstanding15.8412.3811.010.020.930.900.700.690.68
Market Capitalization2,466.292,466.2999.8099.80-----

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other22.7321.4114.8611.3010.189.257.873.13
Research and Development10.8212.479.337.126.535.124.07-0.45
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-22.73-21.41-14.86-11.30-10.18-9.25-7.87-3.13
Interest Expense-2.312.041.741.511.351.220.00
Unusual Expense-0.11-0.090.100.320.120.070.00
Net Income Before Taxes-24.64-21.87-15.77-12.71-11.35-9.47-8.19-2.89
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-24.64-21.87-15.77-12.71-11.35-9.47-8.19-2.89
Net Income From Continuing Operations-24.64-21.87-15.77-12.71-11.35-9.47-8.19-2.89
Net Income-24.64-21.87-15.77-12.71-11.35-9.47-8.19-2.89
EPS (Recurring)-1.70-1.52-1.21-1.08-1.01-0.85-0.74-2.19
EPS (Basic, Before Extraordinaries)-1.70-1.52-1.20-1.08-1.03-0.86-0.74-2.19
EPS (Diluted)-1.70-1.52-1.20-1.08-1.03-0.86-0.74-2.19
EBITDA--21.41-14.86-11.30-10.18-9.25-7.87-3.13
Non-Operating Income (Expense)-1.921.961.040.430.661.250.980.25
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-5.163.382.081.791.431.090.33
Price To Sales Ratio-------16.19
Shares Outstanding15.8414.4014.3112.3811.0911.0611.021.32
Market Capitalization2,466.292,191.871,704.781,238.93693.33249.20314.08315.32

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments57.9883.607.3559.17117.7670.44104.15128.1172.63
Short Term Receivables0.002.340.005.813.311.716.792.7015.55
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.002.300.208.456.553.584.074.571.61
Total Current Assets58.9988.237.5573.42127.6275.72115.01135.3889.79
Net Property, Plant & Equipment0.570.000.0020.7023.0325.9822.945.054.03
Total Investments and Advances0.000.000.000.000.000.000.000.009.92
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.001.372.903.313.150.910.13
Total Assets59.5688.237.5595.49153.56105.01141.10141.34103.88
Short Term Debt Incl. Current Port. of LT Debt0.200.000.000.861.051.030.730.000.00
Accounts Payable4.594.590.944.158.611.795.803.352.45
Other Current Liabilities6.557.451.4231.5740.9019.3320.4744.7343.32
Total Current Liabilities11.3412.042.3636.5850.5622.1427.0048.0845.77
Long Term Debt18.1911.9478.6612.2413.8415.9315.480.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities2.041.651.0118.7338.4035.9147.2653.3346.58
Total Liabilities31.5825.6382.0367.56102.8173.9889.75101.4192.35
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity27.9862.61-74.4827.9350.7631.0351.3539.9411.52
Total Shareholders Equity27.9862.61-74.4827.9350.7631.0351.3539.9411.52
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity27.9862.61-74.4827.9350.7631.0351.3539.9411.52
Total Liabilities & Stockholders Equity59.5688.237.5595.49153.56105.01141.10141.34103.88
Book Value Per Share2.265.69-3,366.1529.9856.2244.3274.4159.0020.48
Tangible Book Value Per Share2.265.69-3,366.1529.9856.2244.3274.4159.0020.48
Full-Time Employees29145014414112312710768
Price to Book Ratio13.510.970.97------
Return on Assets-56.45-27.4736.28-26.72-35.38-30.26-18.04-21.82-25.40
Return on Equity-92.10-39.02-89.76-84.58-111.85-90.39-55.80-103.99-96.04
Return on Invested Capital-90.34-23.39447.80-82.83-70.81-79.28-38.11-66.99-153.16
Quick Ratio5.207.333.202.012.523.424.262.821.96
Current Ratio5.207.333.202.012.523.424.262.821.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--41.72-17.4318.69-33.28-45.74-37.23-25.47-26.75
Depreciation---1.782.782.372.131.040.57
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.160.00-0.16
Other Funds (Non Cash)-12.896.79-29.253.945.185.424.083.39
Funds from Operations--28.82-10.65-10.55-26.56-38.19-29.52-20.35-22.96
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-3.82-0.19-3.15-33.3730.52-16.38-32.1221.89
Cash from Operating Activities--25.01-10.84-13.70-59.93-7.66-45.90-52.47-1.07
Capital Expenditures-0.000.000.00-1.04-0.95-2.73-2.46-1.70
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.00-20.200.0041.9412.30-7.18
Purchase of Investments-0.000.000.00-48.400.00-41.50-59.32-117.58
Sale Or Maturity of Investments-0.000.000.0028.200.0083.4471.62110.41
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.000.000.00-21.24-0.9539.219.84-8.88
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Change in Capital Stock-0.610.000.007.2159.1310.1232.1748.51
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-0.610.000.007.2159.1310.1232.1748.51
Proceedsfrom Stock Options--0.150.000.006.9257.109.6231.0047.21
Issuance or Reduction of Debt, Net-0.0075.760.000.000.000.000.000.00
Change in Long Term Debt-0.0075.760.000.000.000.000.000.00
Issuance of Long Term Debt-0.0075.760.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow--1.2711.335.000.000.000.000.000.00
Other Financing Activities Uses--1.27-2.470.000.000.000.000.000.00
Cash from Financing Activities--0.6687.095.007.2159.1310.1232.1748.51
Exchange Rate Effect-0.050.000.00-5.17-3.194.75-2.14-1.58
Net Change in Cash--25.6276.25-8.70-79.1347.338.18-12.6136.99
Free Cash Flow--25.01-10.84-13.70-60.97-8.61-48.62-54.93-2.76

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments236.68250.58261.8557.9863.5770.43
Short Term Receivables-0.400.300.002.221.98
Inventories-0.000.000.000.000.00
Other Current Assets2.292.041.081.001.151.34
Total Current Assets238.97253.03263.2358.9966.9473.75
Net Property, Plant & Equipment-0.480.530.570.000.00
Total Investments and Advances-0.000.000.000.000.00
Intangible Assets-0.000.000.000.000.00
Other Assets0.430.000.000.000.000.00
Total Assets239.40253.51263.7659.5666.9473.75
Short Term Debt Incl. Current Port. of LT Debt-0.220.210.200.000.00
Accounts Payable-6.795.444.593.484.56
Other Current Liabilities14.934.953.466.556.835.06
Total Current Liabilities14.9311.959.1211.3410.319.62
Long Term Debt-22.4320.1718.1916.0214.51
Provision for Risks Charges-0.000.000.000.000.00
Other Liabilities26.552.272.162.041.921.84
Total Liabilities41.4836.6431.4531.5828.2525.97
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity197.92216.87232.3127.9838.6847.78
Total Shareholders Equity197.92216.87232.3127.9838.6847.78
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity197.92216.87232.3127.9838.6847.78
Total Liabilities & Stockholders Equity239.40253.51263.7659.5666.9473.75
Book Value Per Share12.4915.0616.232.263.494.32
Tangible Book Value Per Share-15.0616.232.263.494.32
Full-Time Employees---29--
Price to Book Ratio13.5110.3569.9730.0014.514.47
Return on Assets-48.96-37.70-28.73---
Return on Equity-63.39-46.63-34.25---
Return on Invested Capital--9.14-6.24-27.53-20.74-15.20
Quick Ratio-21.1828.885.206.497.67
Current Ratio16.0121.1828.885.206.497.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income--21.87-15.77-12.71-11.35-9.47
Other Funds (Non Cash)-7.305.363.983.622.90
Funds from Operations--14.57-10.41-8.73-7.72-6.57
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-1.72-0.463.80-0.151.13
Cash from Operating Activities--12.85-10.86-4.93-7.88-5.43
Capital Expenditures-0.000.000.000.000.00
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments--7.03-55.440.000.000.00
Purchase of Investments--15.03-55.440.000.000.00
Sale Or Maturity of Investments-8.000.000.000.000.00
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities--7.03-55.440.000.000.00
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-1.28230.96-0.050.240.35
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-1.28230.96-0.050.240.35
Proceedsfrom Stock Options-0.00230.00-0.150.000.00
Issuance or Reduction of Debt, Net-0.00-14.250.000.000.00
Change in Long Term Debt-0.00-14.250.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.00-14.250.000.000.00
Net Financing Active Other Cash Flow-0.00-1.980.000.000.00
Other Financing Activities Uses-0.00-1.980.000.000.00
Cash from Financing Activities-1.28214.73-0.050.240.35
Exchange Rate Effect-0.01-0.01-0.610.77-0.11
Net Change in Cash--18.59148.41-5.58-6.87-5.19
Free Cash Flow--12.85-10.86-4.93-7.88-5.43

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3027.97%2.6M9.3M214.14K
2026-10-1526.28%2.4M9.2M213.98K
2026-09-3027.62%2.5M9.1M212.00K
2026-09-1525.45%2.3M9.1M233.53K
2026-08-3125.23%2.3M9.1M256.18K
2026-08-1423.67%2.1M9.1M252.68K
2026-07-3120.34%2.1M10.2M264.28K
2026-07-1521.49%2.2M10.1M260.94K
2026-06-3023.36%2.4M10.1M266.19K
2026-06-1520.52%2.1M10.1M249.68K
2026-05-2920.93%2.1M10.1M242.84K
2026-05-1521.22%2.1M10.1M300.26K
2026-04-3020.99%2.2M10.3M311.79K
2026-04-1519.18%2.0M10.3M320.50K
2026-03-3122.42%2.2M9.7M315.27K
2026-03-1320.79%1.9M9.3M330.21K
2026-02-2721.73%1.7M8.0M313.03K
2026-02-1320.86%1.7M8.0M280.09K
2026-01-3016.96%1.4M8.1M260.64K
2026-01-1516.76%1.4M8.1M240.10K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call55.00107111.50.005.2220.000.000.979-0.2980.013
call60.00101.5106.51114.8431.000.000.978-0.2970.014
call65.0096.50101.5109.414.4980.000.000.976-0.2950.015
call70.0091.5096.500.004.1800.000.000.974-0.2930.016
call75.0086.5091.5070.803.8861.000.000.972-0.2900.017
call80.0081.5086.5066.403.6121.000.000.969-0.2880.018
call85.0076.5081.500.003.1920.000.000.967-0.2850.019
call90.0071.5076.5037.002.9593.000.000.964-0.2810.020
call95.0066.5071.5048.022.7380.000.000.961-0.2770.021
call10061.5066.500.002.6640.000.000.958-0.2730.023
call10556.5061.5042.002.4552.000.000.941-0.3570.030
call11051.6056.5050.502.1341.000.000.913-0.5040.040
call11547.1051.5015.782.0624.000.000.905-0.4910.043
call12042.5046.5025.501.7691260.000.896-0.4770.046
call12537.3041.5021.801.5954.000.000.886-0.4610.049
call13032.1036.505.001.42514.000.000.830-0.6840.064
call13527.0031.5027.501.2586.000.000.813-0.6520.069
call14022.4026.5024.201.09364.000.000.792-0.6150.073
call14517.8022.0023.401.0038.002.000.766-0.5730.078
call15013.7017.5026.000.9583220.000.734-0.5180.084
call1559.6013.5013.960.8811.000.000.686-0.4620.090
call1606.5010.009.700.82611.000.000.610-0.4140.098
call1653.107.509.680.7790.000.000.506-0.4540.102
call1700.805.5010.000.7831.000.000.407-0.4390.099
call1750.004.900.600.8910.000.000.342-0.4690.094
call1800.004.905.001.04017.000.000.311-0.5340.090
call1850.004.904.001.1771.000.000.287-0.5830.087
call1900.004.903.131.3031.000.000.267-0.6230.084
call1950.004.909.301.4212.000.000.252-0.6580.081
call2000.004.901.651.5331.000.000.239-0.6900.079
call2100.004.901.951.7382.000.000.219-0.7440.075
call2200.004.901.251.9252.000.000.204-0.7890.072
call2300.004.900.852.0321.000.000.194-0.8190.071
call2400.004.901.552.2582.000.000.182-0.8650.067
call2500.004.900.002.3250.000.000.176-0.8770.067
call2600.004.900.002.5070.000.000.168-0.9120.065
put55.000.004.900.004.0710.000.00-0.020-0.2860.013
put60.000.004.900.003.7800.000.00-0.022-0.2840.014
put65.000.004.900.003.5060.000.00-0.024-0.2820.015
put70.000.004.900.003.2610.000.00-0.025-0.2800.016
put75.000.004.905.503.0251.000.00-0.027-0.2770.017
put80.000.004.902.302.8091.000.00-0.030-0.2740.018
put85.000.004.903.302.6051.000.00-0.032-0.2700.019
put90.000.004.900.102.41332.000.00-0.034-0.2670.020
put95.000.004.905.902.2052.000.00-0.039-0.2670.021
put1000.001.001.502.0086.000.00-0.039-0.2400.024
put1050.004.900.002.0440.000.00-0.059-0.3450.030
put1100.002.552.552.1451.000.00-0.081-0.4540.042
put1150.002.559.502.3630.000.00-0.118-0.6550.055
put1200.004.500.051.79319.003.00-0.104-0.4640.046
put1250.002.552.482.0510.000.00-0.144-0.6530.063
put1300.005.008.001.8451.000.00-0.170-0.6700.064
put1350.004.900.001.6510.000.00-0.187-0.6370.069
put1400.004.900.001.4600.000.00-0.208-0.6000.073
put1450.004.905.501.26930.000.00-0.234-0.5570.078
put1500.004.900.701.0770.001.00-0.266-0.4990.084
put1550.004.901.150.8804.001.00-0.314-0.4450.090
put1601.004.900.000.6720.000.00-0.390-0.3960.098
put1653.508.303.800.76915.000.00-0.494-0.4360.102
put1706.5011.000.000.7440.000.00-0.593-0.4200.099
put17510.0014.809.300.78412.000.00-0.658-0.4490.094
put18014.5018.8032.500.8101.000.00-0.689-0.5140.090
put18519.0023.3046.500.8693.000.00-0.713-0.5620.087
put19024.0028.5054.701.0114.000.00-0.733-0.6020.084
put19528.5032.8047.001.0101.000.00-0.748-0.6360.081
put20033.5038.0031.001.1581.001.00-0.761-0.6670.079
put21043.5047.700.001.2690.000.00-0.781-0.7210.075
put22053.5058.4058.501.5470.000.00-0.796-0.7650.072
put23063.5068.400.001.7050.000.00-0.808-0.8040.070
put24073.5077.900.001.7700.000.00-0.818-0.8380.067
put25083.5087.8081.001.8830.002.00-0.826-0.8690.066
put26093.5097.800.002.0090.000.00-0.832-0.8960.064

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-28SCHEDULE 13G/ASEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-10SCHEDULE 13GSEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-03SCHEDULE 13GSEC
2026-07-29SCHEDULE 13GSEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-15144Filing for proposed sale of securities under Rule 144.SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-013Initial statement of beneficial ownership of securities2026-06-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10004.12M4
2026-09004.87M5
2026-0800654.79K1
2026-0700642.19K1
2026-0600476.37K1
2026-0500475.63K1
2026-0400547.40K1
2026-0349.97K1507.61K1
2026-02800.00K2341.56K1
2026-0100419.98K1
2025-1200415.02K1
2025-1100370.97K1

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC7.92%
JENNISON ASSOCIATES LLC6.70%
BlackRock, Inc.6.40%
Frazier Life Sciences Management, L.P.6.15%
First Light Asset Management, LLC5.38%
BVF INC/IL4.69%
STATE STREET CORP4.55%
PRICE T ROWE ASSOCIATES INC /MD/4.45%
VANGUARD CAPITAL MANAGEMENT LLC3.58%
FRONTIER CAPITAL MANAGEMENT CO LLC3.34%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF2.85%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.71%
iShares Russell 2000 ETF1.96%
Federated Hermes Kaufmann Fund1.93%
Eventide Healthcare & Life Sciences Fund1.61%
PRIMECAP Odyssey Aggressive Growth Fund1.46%
PGIM Jennison Small Company Fund1.41%
PGIM Jennison Health Sciences Fund1.33%
T. Rowe Price New Horizons Fund, Inc.1.14%
Federated Hermes Kaufmann Small Cap Fund1.05%

OakChart. PVLA. Cached 15 minutes.